Differential diagnostic challenge of chronic neutrophilic leukemia in a patient with prolonged leukocytosis.

Neureiter D, Kemmerling R, Ocker M, Seidlhofer C, Faber V, Stöcher M, Greil R, Dietze O. J Hematop. 2008 Jul,1(1):23-7. doi: 10.1007/s12308-008-0004-x. Epub 2008 Apr 19.

Is Chemoendocrine Treatment without Alternative?

Greil R. Breast Care (Basel). 2008,3(4):231-235. Epub 2008 Aug 22.

T Cell Dynamics during the Pretumor and Tumor Phase in the Murine Tcll Transgenic Chronic Lymphocytic Leukemia Model

Egle, A, Pinon, JD, Heyder, C, Holler, C, Denk, U, Tinhofer, I, Greil, R BLOOD. 2008, 112(11): 1078-1078.

Minimal Residual Disease (MRD) and T/NK Cell Dynamics during Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): Riskfactor Stratification in the Chairos Study.

Egle, A, Weiss, L, Gassner, F, Russ, G, Pleyer, L, Gunsilius, E, Tinhofer, I, Thaler, J, Petzer, AL, Greil, R BLOOD. 2008, 112(11): 1089-1089.

Fulvestrant (‚Faslodex‘) in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.

Mlineritsch B, Psenak O, Mayer P, Moik M, Namberger K, Hauser-Kronberger C, Greil R. Breast Cancer Res Treat. 2007 Nov,106(1):105-12. Epub 2007 Feb 13.

Is it time to consider neoadjuvant treatment as the standard of care in oesophageal cancer?

Greil R, Stein HJ. Lancet Oncol. 2007 Mar,8(3):189-90.

Hematopoietic growth factors: ESMO recommendations for the application.

ESMO Guidelines Working Group, Greil R, Psenak O. Ann Oncol. 2007 Apr,18 Suppl 2:ii89-91.

Massive infiltration of bone marrow in colon carcinoma after treatment with activated protein C.

Pleyer L, Went P, Russ G, Prinz E, Faber V, Röwert HJ, Karlbauer R, Greil R. Wien Klin Wochenschr. 2007,119(7-8):254-8.

Systemic application of granulocyte-colony stimulating factor and stem cell factor exacerbates excitotoxic brain injury in newborn mice.

Keller M, Simbruner G, Gorna A, Urbanek M, Tinhofer I, Griesmaier E, Sarkozy G, Schwendimann L, Gressens P. Pediatric Research. 2006 Apr, 59 (4 Pt 1): 549-53.

Wie sterben wir? Wie schГ¶n ist der Tod? Wie teuer ist der Tod? – Die Palliativmedizin im Spannungsfeld der Ressourcenallokation

Greil, R, In: Fischer, M, Zänker, KS, editors(s). Medizin- und Bioethik. (ISBN: 978-3-631-54744-1 )